The company intends to unveil the new technology at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting. It said the platform showcases the integration of advanced AIR technologies with SIGNA, enhancing diagnostic precision. Signa also can simplify treatment evaluation and elevate patient comfort, GE HealthCare said in a news release.
GE HealthCare says the AIR technologies incorporated into Signa address the evolving demands of a range of patient populations. New PET radiotracers and therapeutic approaches treat high-prevalence diseases such as prostate cancer and Alzheimer’s disease.
The system features AIR Coils, which enhance and improve patient comfort, GE HealthCare says. It also includes AIR Recon DL, which improves MR image quality and enables scan time reduction. The company touts Signa’s MotionFree Brain offering that mitigates motion-related PET image degradation, too.
What comprises the GE HealthCare Signa system?
Integrating PSMA-targeted PET radiotracers with GE HealthCare’s precise MRI in Signa could potentially offer precise diagnosis. The company says it also enables the staging and re-staging of prostate cancer and can help select patients for PSMA-targeted radioligand therapy.
Signa PET/MR AIR delivers deep learning-based MR image reconstruction with AIR Recon DL. It ensures both improved image quality and a reduction of scan time by up to 50%, GE HealthCare says. The AIR Coil effortlessly conforms to the shape of the human body, enhancing MR image quality while enhancing patient comfort, too.
MotionFree Brain PET manages motion without external tracking devices. GE HealthCare said it helps to ensure consistent image quality, even in challenging patients. This could enable faster and more accurate diagnoses and minimize the need for repeat scans.
“The Signa PET/MR AIR system continues our legacy of delivering innovative technologies that address a comprehensive range of clinical diseases,” said Jie Xue, president and CEO of MR at GE HealthCare. “Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer’s disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring.
“We are excited to see Signa PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”
